Ranbaxy Buyers' $485M Deal In Generics MDL Gets Initial Nod
Ranbaxy Pharmaceuticals drug purchasers nabbed initial approval of a $485 million global settlement struck in March over claims the drugmaker manipulated the U.S. Food and Drug Administration's generic-drug approval process to...To view the full article, register now.
Already a subscriber? Click here to view full article